U.S. Life Sciences Stock News

Core Scientific (CORZ) just posted its FY 2025 Q4 numbers, reporting revenue of US$79.8 million, basic EPS of US$0.68 and net income of US$216.0 million. The company has seen quarterly revenue move in a tight band between US$78.6 million and US$95.4 million since late 2024, while basic EPS has swung from a loss of US$1.17 per share in 2024 Q3 to a profit of US$0.68 in 2025 Q4, highlighting how volatile margins have been for shareholders tracking the story. With trailing twelve month EPS still...

If you are wondering whether Church & Dwight is offering fair value at its current share price, you are not alone. This article is built to help you assess what you are really paying for. The stock last closed at US$103.02, with a 7.0% return over the past 30 days, a 24.7% return year to date, but a 5.7% decline over the past year and longer term returns of 27.6% over 3 years and 35.9% over 5 years. Recent interest in Church & Dwight reflects its position as a long established household...

Wondering whether Stoke Therapeutics at around US$33.78 is starting to look expensive or if there is still value on the table? This article walks through the key numbers so you can judge for yourself. The stock has been volatile, with a 4.8% decline over the last 7 days, an 11.3% gain over 30 days, a 9.3% return year to date, a 345.6% return over 1 year, a 266.0% return over 3 years, and a 34.9% decline over 5 years. These price swings sit against a backdrop of ongoing attention on Stoke...

CACI International (NYSE:CACI) has announced and priced a $500 million senior notes offering. The company plans to use the proceeds to help fund its acquisition of ARKA Group L.P. The transaction affects CACI International's capital structure and future debt obligations. For investors watching NYSE:CACI, this new senior notes offering comes at a time when the stock is trading at $629.75. The shares show longer term returns of 78.4% over the past year, 110.5% over three years, and 182.1%...

If you are wondering whether Palantir Technologies' current share price still makes sense after everything that has happened with the stock, this article will walk you through what the current market price could be implying about its value. The stock closed at US$147.22, with returns of 9.7% over the last 7 days, a 0.4% decline over 30 days, a 12.3% decline year to date, 63.3% over 1 year, and a very large gain over 3 years, which naturally raises questions about how much optimism is already...

Conference appearance puts U.S. Gold in focus U.S. Gold (USAU) is set to present at the Emerging Growth Virtual Conference on February 25, 2026. Executive Chairman Luke Anthony Norman is expected to speak, drawing attention to potential commentary on projects and capital needs. See our latest analysis for U.S. Gold. At a share price of US$18.84, U.S. Gold has seen a 7 day share price return of 4.96% and a 30 day share price return of 8.65%. The 1 year total shareholder return of 125.90% and 3...

Agios Pharmaceuticals recently announced that the Emirates Drug Establishment in the UAE approved PYRUKYND (mitapivat) as the first and only medicine for adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. This approval, supported by global Phase 3 ENERGIZE and ENERGIZE-T data and backed by a regional partnership with NewBridge Pharmaceuticals, strengthens Agios’s push into Gulf markets for rare blood disorder treatments. Next, we’ll examine...

Axos Financial (AX) has been in focus after higher than expected inflation data raised doubts about near term rate cuts, putting pressure on bank stocks and sharpening investor attention on interest rate risk. See our latest analysis for Axos Financial. Despite the inflation driven sell off that recently hit Axos Financial, the current US$89.97 share price sits above its 90 day level, and the 1 year and 3 year total shareholder returns of 39.92% and 97.82% suggest momentum has been positive...

Harry Potter tie-in puts McCormick’s Butterbeer flavors in focus McCormick (MKC) is back in the spotlight after partnering with Warner Bros. Discovery to launch limited edition Harry Potter Butterbeer Finishing Sugar and Butterbeer Flavor across major retailers. The collaboration gives investors a fresh data point on how licensing deals and themed products might influence McCormick’s broad consumer portfolio, which already spans spices, sauces, seasonings, and dessert products worldwide. See...

AbbVie recently reported positive topline Phase 3 results from its AFFIRM trial, showing risankizumab (SKYRIZI) subcutaneous induction led to significantly higher clinical remission and endoscopic response rates than placebo in adults with moderately to severely active Crohn’s disease, with safety consistent with prior data. Because AFFIRM included patients who had already failed multiple advanced therapies, the results highlight SKYRIZI’s potential to address a difficult-to-treat Crohn’s...

The Morning Bull - US Market Morning Update Wednesday, Mar, 4 2026 US stock futures are slightly softer this morning, with E-mini S&P 500 contracts down about 0.2%, as investors juggle stubborn inflation worries and mixed global growth signals. The US 10 year Treasury yield is holding near 4.06%, which indicates borrowing costs remain relatively high and keeps pressure on areas like real estate and smaller, debt heavy companies. At the same time, a large 5.6 million barrel build in US oil...

What Medline’s recent fundamentals mean for investors Medline (MDLN) has drawn fresh attention after investors focused on its latest reported fundamentals, including US$28.4b in revenue, US$1.2b in net income, and single digit annual growth rates across both measures. See our latest analysis for Medline. Despite US$28.4b of revenue and US$1.2b of net income drawing focus to fundamentals, Medline’s recent 1-day share price return of a 3.18% decline and 7-day share price return of an 11.2%...

In February 2026, Peoples Group announced a major partnership with Fiserv to power its next-generation Canadian payments infrastructure using Fiserv’s Enterprise Payments Platform and DNA core in the public cloud, supporting instant payments, always-on connectivity, and ISO 20022 data ahead of Payments Canada’s Real-Time Rail rollout. This represents one of Peoples Group’s largest technology investments and highlights how Fiserv’s cloud-based payments stack is increasingly becoming a...

Cavco Industries triggered stock overview Cavco Industries (CVCO) has drawn investor attention after recent share price moves, with the stock up about 15% over the past month while the past 3 months show a modest decline. See our latest analysis for Cavco Industries. While Cavco’s 30 day share price return of 14.5% stands out, year to date share price performance is softer, and the longer term total shareholder returns of 8.5% over 1 year and 154.3% over 5 years show a very different...

AMETEK (AME) is in focus after reporting Q4 2025 earnings and revenue above forecasts, lifting its 2026 outlook, outlining a $100 million growth investment, and announcing a dividend increase that caught investors’ attention. See our latest analysis for AMETEK. Despite a 2.6% one day share price decline and a flat week, AMETEK’s 5.0% 30 day and 18.1% 90 day share price returns, alongside a 1 year total shareholder return of 29.2%, suggest momentum has recently been building. If this update...

GXO Logistics (NYSE:GXO) has entered a new partnership with lingerie retailer Hunkemoller to manage its B2B logistics. The agreement covers operations at a state of the art facility in Almere and is structured as a multi year deal. This is Hunkemoller’s first time outsourcing its B2B logistics operations to an external provider. For you as an investor, this move highlights how GXO Logistics (NYSE:GXO) positions itself as a specialist in complex, tech driven logistics for retailers. The...

NextDecade (NasdaqCM:NEXT) approved positive final investment decisions on Trains 4 and 5 at its Rio Grande LNG Facility. The company executed multiple long term LNG sale and purchase agreements tied to these additional trains. These steps expand NextDecade's planned LNG production capacity and build out its contracted commercial portfolio. NextDecade focuses on developing LNG export capacity at its Rio Grande LNG Facility, positioning itself as a US Gulf Coast supplier to global buyers...

Rumors are circulating that Sanofi is considering a significantly higher acquisition bid for Ocular Therapeutix (NasdaqGM:OCUL). The speculation follows recent regulatory developments that may create new or faster FDA approval routes for the company’s ophthalmology programs. Market attention has increased as investors assess what a larger potential offer and altered commercialization timelines could mean for OCUL’s valuation and future role in eye care. Ocular Therapeutix focuses on...

Kyndryl Holdings, Inc. recently reported a past quarter where revenue grew but missed analyst expectations and EPS fell short, even as it expanded AI, cloud, and security offerings, launched a Cyber Defense Operations Center in India, and advanced healthcare AI collaborations in the UK. These developments highlight Kyndryl’s push into integrated AI, cybersecurity, and digital sustainability services, even as weaker earnings raised questions about how quickly that shift can translate into...

In the past week, insurance software provider Guidewire Software announced a multi-year partnership with Sompo Group to roll out its cloud platform globally, received board approval for a share repurchase program, and prepared to report earnings following a quarter that beat revenue expectations but missed billings estimates. Together, the Sompo collaboration, upcoming earnings release, and new buyback authorization highlight how Guidewire is trying to deepen insurer relationships while...

What recent returns say about Marathon Petroleum stock Recent trading in Marathon Petroleum (MPC) has caught investor attention, with the shares showing positive moves over the past week, month, and past 3 months, as well as on a 1 year and multi year basis. Against that backdrop, it is worth looking at how the company’s current valuation metrics, profitability, and business mix across refining, midstream, and renewable diesel compare with the recent share performance. See our latest analysis...

In late February 2026, Arista Networks reported strong fourth-quarter results and lifted its full-year growth outlook and AI revenue forecast to US$3.25 billion, largely driven by accelerating demand from Cloud and AI customers. This shift means AI-related networking could contribute about 30% of Arista’s total revenue this year, with up to four customers each accounting for more than 10% of sales, underscoring both the scale of demand and the concentration of its client base. With Arista...

CBIZ (NYSE:CBZ) reported weak underlying organic growth, while headline revenue gains were largely driven by acquisitions. Management flagged that some mid market client projects were postponed and issued a modest growth outlook for 2026. The update points to softer demand from key mid market clients and a greater reliance on acquired revenue. For investors watching NYSE:CBZ, the latest update comes after a sharp share price reset, with the stock down 24.1% over the past month and 41.2%...

Fidelity National Information Services (FIS) just paired strong Q4 and 2025 earnings with an ambitious 2026 revenue outlook, backed by new AI products and fresh bond offerings that reshape how investors might think about its capital structure. See our latest analysis for Fidelity National Information Services. Even with the recent Q4 beat, guidance and new AI products, the 90 day share price return of 23.44% and 2026 price target cuts have kept the latest share price around US$50. That short...